Clinical Study
Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Table 2
Cox multivariate regression analysis of preoperative and histopathologic parameters.
| Parameter | Overall survival | Cancer-specific survival | Biochemical progression free survival | HR | 95% CI | value | HR | 95% CI | value | HR | 95% CI | value |
| Pathological stage | 0.195 | 0.052–0.735 | 0.016 | 0.00 | 0.00–9.80 | 0.923 | 0.475 | 0.291–0.775 | 0.003 | Age | 1.06 | 0.977–1.152 | 0.162 | 1.068 | 0.943–1.208 | 0.29 | 1.005 | 0.969–1.043 | 0.779 | Lymph node | 0.546 | 0.158–1.88 | 0.337 | 0.832 | 0.166–4.276 | 0.823 | 0.715 | 0.542–0.943 | 0.018 | Pre operative PSA | 1.013 | 0.982–1.046 | 0.406 | 1.007 | 0.964–1.051 | 0.766 | 1.005 | 0.991–1.019 | 0.490 | Surgical margins | 0.878 | 0.220–3.514 | 0.855 | 0.522 | 0.058–4.686 | 0.562 | 0.756 | 0.440–1.30 | 0.312 | Biopsy Gl. score | 1.072 | 0.600–1.915 | 0.814 | 1.093 | 0.530–2.251 | 0.81 | 1.077 | 0.792–1.466 | 0.636 | Surgery Gl. score | 2.82 | 1.492–5.337 | 0.001 | 3.24 | 1.018–10.311 | 0.04 | 2.029 | 1.461–2.818 | 0.0001 |
|
|